Every material Form 8-K Alamar Biosciences, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alamar Biosciences reported third-quarter 2026 revenue of $33.5 million, up 68% from a year earlier, and raised its full-year 2026 revenue guidance to $121 million to $123 million. The net loss widened to $13.3 million from $8.0 million as operating expenses rose 81%, though per-share loss narrowed to $0.19 from $0.69 on a much larger share count. President Tod White, who previously served as chief financial officer, will retire at the end of 2026 and remain a consultant through June 30, 2027.
Q3 2026 total revenue was $33.5 million, up from $19.9 million; consumable revenue was $17.8 million.
Full-year 2026 revenue guidance raised to $121 million to $123 million, from the prior $116 million to $120 million.
Net loss was $13.3 million versus $8.0 million a year earlier; operating expenses were $35.8 million, up 81%.
President Tod White retires December 31, 2026; he will consult from January 1, 2027 through June 30, 2027.
Alamar Biosciences appointed Robert Ragusa to its board of directors, effective September 1, 2026, as a Class I director with a term expiring at the 2027 annual meeting. He also joined the audit, compensation, and nominating and corporate governance committees. The filing describes this as a routine board addition with no related person transactions disclosed.
Robert Ragusa appointed to the Board by action on August 28, 2026, effective September 1, 2026
Class I director; initial term expires at the 2027 Annual Meeting of Stockholders
Also named to Audit, Compensation, and Nominating and Corporate Governance Committees
Compensated under the Non-Employee Director Compensation Policy described in the April 17, 2026 final prospectus
Alamar Biosciences reported second-quarter 2026 revenue of $29.4 million, up 82% from a year earlier, and gave full-year 2026 revenue guidance of $116 million to $120 million. The net loss widened to $13.2 million from $7.0 million as operating expenses rose 89%, so shareholders face strong sales growth alongside a larger loss.
Q2 2026 total revenue was $29.4 million, up from $16.2 million in Q2 2025; consumable revenue rose 147% to $15.5 million
Q2 2026 net loss was $13.2 million versus $7.0 million a year earlier; operating expenses rose to $31.2 million from $16.5 million
Full-year 2026 revenue guidance is $116 million to $120 million, growth of 59% at the midpoint versus 2025
Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million as of June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alamar Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →